DE20308436U1 - Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst - Google Patents
Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasstInfo
- Publication number
- DE20308436U1 DE20308436U1 DE20308436U DE20308436U DE20308436U1 DE 20308436 U1 DE20308436 U1 DE 20308436U1 DE 20308436 U DE20308436 U DE 20308436U DE 20308436 U DE20308436 U DE 20308436U DE 20308436 U1 DE20308436 U1 DE 20308436U1
- Authority
- DE
- Germany
- Prior art keywords
- preparation according
- preparation
- naloxone
- oxycodone
- magnesium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Description
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Claims (32)
1. Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst,
dadurch gekennzeichnet, dass die Wirkstoffe aus dem Präparat verzögert, gleichbleibend
und unabhängig voneinander freigesetzt werden.
2. Präparat nach Anspruch 1,
dadurch gekennzeichnet, dass Oxycodon bzw. Naloxon in Form ihrer pharmazeutisch
verwendbaren und gleich wirkenden Derivate derselben, wie der Base, Salze und dergleichen
vorliegen.
3. Präparat nach Anspruch 2,
dadurch gekennzeichnet, dass Oxycodon bzw. Naloxon als Hydrochlorid, Sulfat, Bisulfat,
Tatrat, Nitrat, Zitrat, Bitratrat, Phosphat, Malat, Maleat, Hydrobromid, Hydrojodid, Fumarat
oder Succinat vorliegen.
4. Präparat nach einem der vorstehenden Ansprüche,
dadurch gekennzeichnet, dass Oxycodon bezogen auf die Einheitsmenge von Naloxon im
Überschuss vorliegt.
5. Präparat nach einem der vorstehenden Ansprüche,
dadurch gekennzeichnet, dass Naloxon in einem Mengenbereich von 1 bis 50 mg vorliegt.
6. Präparat nach einem der vorstehenden Ansprüche,
dadurch gekennzeichnet, dass Oxycodon in einem Mengenbereich von 10 bis 150 mg,
bevorzugt von 10 bis 80 mg vorliegt.
7. Präparat nach einem der vorstehenden Ansprüche,
dadurch gekennzeichnet, dass es Oxycodon und Naloxon im Gewichtsverhältnisbereich von
maximal 25 : 1, vorzugsweise maximal 20 : 1, 15 : 1, besonders bevorzugt von 5 : 1, 4 : 1, 3 : 1,
2 : 1 oder 1 : 1 enthält.
8. Präparat nach einem der vorstehenden Ansprüche,
dadurch gekennzeichnet, dass das Präparat eine im wesentlichen nicht-quellende und nicht
erodierende Diffusionsmatrix umfasst.
9. Präparat nach Anspruch 8
dadurch gekennzeichnet, dass die Diffusionsmatrix als die das Freisetzungsverhalten der
Wirkstoffe im wesentlichen beeinflussende Bestandteile wenigstens Ethylcellulose und
mindestens einen Fettalkohol enthält.
10. Präparat nach Anspruch 8 oder Anspruch 9,
dadurch gekennzeichnet, dass das Präparat keine relevanten Gehalte an alkalischen und/oder
wasserquellbaren Substanzen, insbesondere Acrylsäurederivaten und/oder Hydroxyalkyl
zellulosen, umfasst.
11. Präparat nach einem der vorstehenden Ansprüche,
dadurch gekennzeichnet, dass das Präparat übliche Füll- und Hilfsstoffe, insbesondere
Schmiermittel, Fließmittel, Weichmacher und dergleichen umfasst.
12. Präparat nach Anspruch 11,
dadurch gekennzeichnet, dass es sich bei dem Schmiermittel um Magnesiumstearat,
Calciumstearat und/oder Calciumlaureat und/oder Fettsäuren, besonders bevorzugt um
Stearinsäure handelt.
13. Präparat nach Anspruch 11,
dadurch gekennzeichnet, dass es sich bei dem Fließmittel um hochdisperse Kieselsäure,
besonders bevorzugt Aerosil®, Talkum, Maisstärke, Magnesiumoxid, Magnesium- und/oder
Calciumstearat handelt.
14. Lagerstabiles pharmazeutisches Präparats, das Oxycodon und Naloxon in einer
im wesentlichen nicht-quellenden Diffusionsmatrix umfasst,
dadurch gekennzeichnet, dass die Matrix in ihren wesentlichen Freisetzungseigenschaften
durch Ethylcellulose und mindestens einen Fettalkohol ausgeprägt wird und das Präparat
Oxycodon und Naloxon im Gewichtsverhältnisbereich von maximal 25 : 1, vorzugsweise
maximal 20 : 1, 15 : 1, besonders bevorzugt von 5 : 1, 4 : 1, 3 : 1, 2 : 1 oder 1 : 1 enthält.
15. Präparat nach Anspruch 14,
dadurch gekennzeichnet, dass Oxycodon bzw. Naloxon in Form ihrer pharmazeutisch
verwendbaren und gleich wirkenden Derivate derselben, wie der freien Base, als Salze und
dergleichen vorliegen.
16. Präparat nach Anspruch 15,
dadurch gekennzeichnet, dass Oxycodon bzw. Naloxon als Hydrochlorid, Sulfat, Bisulfat,
Tatrat, Nitrat, Zitrat, Bitratrat, Phosphat, Malat, Maleat, Hydrobromid, Hydrojodid, Fumarat
oder Succinat vorliegt.
17. Präparat nach einem der Ansprüche 14 bis 16,
dadurch gekennzeichnet, dass der Oxycodon bezogen auf die Einheitsmenge von Naloxon
im Überschuss vorliegt.
18. Präparat nach einem der Ansprüche 14 bis 17,
dadurch gekennzeichnet, dass Naloxon in einem Mengenbereich von 1 bis 50 mg vorliegt.
19. Präparat nach einem der Ansprüche 14 bis 18,
dadurch gekennzeichnet, dass Oxycodon in einem Mengenbereich von 10 bis 150 mg,
bevorzugt von 10 bis 80 mg vorliegt.
20. Präparat nach einem der Ansprüche 14 bis 19,
dadurch gekennzeichnet, dass das Präparat eine im wesentlichen nicht-quellende und nicht
erodierende Diffusionsmatrix umfasst.
21. Präparat nach Anspruch 20
dadurch gekennzeichnet, dass die Diffusionsmatrix als die das Freisetzungsverhalten der
Wirkstoffe im wesentlichen beeinflussende Bestandteile wenigstens Ethylcellulose und
mindestens einen Fettalkohol enthält.
22. Präparat nach Anspruch 20 oder 21,
dadurch gekennzeichnet, dass das Präparat keine relevanten Gehalte an alkalischen und/oder
wasserquellbaren Substanzen, insbesondere Acrylsäurederivaten und/oder Hydroxyalkyl
zellulosen, umfasst.
23. Präparat nach einem der Ansprüche 14 bis 22,
dadurch gekennzeichnet, dass es sich bei den Fettalkoholen um Lauryl-, Myrestyl-, Stearyl-,
Cetostearyl-, Ceryl- und/oder Cetylalkohol, besonders bevorzugt um Stearylalkohol handelt.
24. Präparat nach einem der Ansprüche 14 bis 23,
dadurch gekennzeichnet, dass das Präparat übliche Füll- und Hilfsstoffe, insbesondere
Schmiermittel, Fließmittel, Weichmacher und dergleichen umfasst.
25. Präparat nach Anspruch 24,
dadurch gekennzeichnet, dass es sich bei dem Schmiermittel um Magnesiumstearat,
Calciumstearat und/oder Calciumlaureat und/oder Fettsäuren, besonders bevorzugt um
Stearinsäure handelt.
26. Präparat nach Anspruch 24,
dadurch gekennzeichnet, dass es sich bei dem Fließmittel um hochdisperse Kieselsäure,
besonders bevorzugt Aerosil®, Talkum, Maisstärke, Magnesiumoxid, Magnesium- und/oder
Calciumstearat handelt.
27. Präparat nach einem der vorstehenden Ansprüche,
dadurch gekennzeichnet,
dass anstelle von Ethylcellulose kommerziell erhältliche Polymermischungen, die
Ethylcellulose enthalten, bevorzugt Surelease® E-7-7050 verwendet wird.
28. Präparat nach einem der vorstehenden Ansprüche,
dadurch gekennzeichnet, dass das Präparat zur oralen, nasalen, rektalen oder zur
Applikation per inhalationem formuliert ist.
29. Präparat nach einem der vorstehenden Ansprüche,
dadurch gekennzeichnet, dass es sich bei dem Präparat um eine Tablette, Dragee, Kapsel,
Granulat und/oder Pulver handelt.
30. Präparat nach einem der vorstehenden Ansprüche,
dadurch gekennzeichnet, dass das Präparat oder Vorstufen davon durch Aufbau- und/oder
Abbaugranulation hergestellt wird.
31. Präparat nach einem der vorstehenden Ansprüche,
dadurch gekennzeichnet, dass das Präparat oder Vorstufen davon durch Extrusion
hergestellt wird.
32. Präparat nach einem der vorstehenden Ansprüche,
dadurch gekennzeichnet, dass das Präparat wenigstens 2 Jahre unter Standardbedingungen
(60% relative Feuchte, 25°C) zulassungskonform lagerfähig ist.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE20308436U DE20308436U1 (de) | 2002-04-05 | 2003-04-04 | Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10215067A DE10215067A1 (de) | 2002-04-05 | 2002-04-05 | Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst |
DE10215131A DE10215131A1 (de) | 2002-04-05 | 2002-04-05 | Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen |
DE20308436U DE20308436U1 (de) | 2002-04-05 | 2003-04-04 | Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst |
Publications (1)
Publication Number | Publication Date |
---|---|
DE20308436U1 true DE20308436U1 (de) | 2003-09-18 |
Family
ID=28676052
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE17169621.4T Pending DE17169621T1 (de) | 2002-04-05 | 2003-04-04 | Pharmazeutische zubereitung mit oxycodon und naloxon |
DE20308437U Expired - Lifetime DE20308437U1 (de) | 2002-04-05 | 2003-04-04 | Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen |
DE60325567T Expired - Lifetime DE60325567D1 (de) | 2002-04-05 | 2003-04-04 | Matrix für die modifizierte freigabe von aktiven substanzen |
DE17154462.0T Pending DE17154462T1 (de) | 2002-04-05 | 2003-04-04 | Matrix für nachhaltige, invariante und unabhängige freisetzung von wirkstoffverbindungen |
DE20321531U Expired - Lifetime DE20321531U1 (de) | 2002-04-05 | 2003-04-04 | Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfaßt |
DE20308436U Expired - Lifetime DE20308436U1 (de) | 2002-04-05 | 2003-04-04 | Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE17169621.4T Pending DE17169621T1 (de) | 2002-04-05 | 2003-04-04 | Pharmazeutische zubereitung mit oxycodon und naloxon |
DE20308437U Expired - Lifetime DE20308437U1 (de) | 2002-04-05 | 2003-04-04 | Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen |
DE60325567T Expired - Lifetime DE60325567D1 (de) | 2002-04-05 | 2003-04-04 | Matrix für die modifizierte freigabe von aktiven substanzen |
DE17154462.0T Pending DE17154462T1 (de) | 2002-04-05 | 2003-04-04 | Matrix für nachhaltige, invariante und unabhängige freisetzung von wirkstoffverbindungen |
DE20321531U Expired - Lifetime DE20321531U1 (de) | 2002-04-05 | 2003-04-04 | Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfaßt |
Country Status (33)
Country | Link |
---|---|
US (11) | US20050245483A1 (de) |
EP (17) | EP2316428A1 (de) |
JP (5) | JP4620355B2 (de) |
KR (3) | KR100784341B1 (de) |
CN (4) | CN102813654A (de) |
AP (2) | AP2397A (de) |
AR (3) | AR039378A1 (de) |
AT (1) | ATE418967T2 (de) |
AU (2) | AU2003224041B2 (de) |
BR (2) | BR0309004A (de) |
CA (3) | CA2708900C (de) |
CO (2) | CO5611100A2 (de) |
CY (5) | CY1108914T1 (de) |
DE (6) | DE17169621T1 (de) |
DK (6) | DK1492506T4 (de) |
ES (7) | ES2627300T3 (de) |
FI (1) | FI7846U1 (de) |
GE (3) | GEP20064022B (de) |
HK (5) | HK1072366A1 (de) |
HU (4) | HUE032656T2 (de) |
IL (5) | IL163990A0 (de) |
LT (3) | LT2425825T (de) |
MA (2) | MA27116A1 (de) |
MX (2) | MXPA04009713A (de) |
NZ (1) | NZ535286A (de) |
PH (1) | PH12018000176A1 (de) |
PT (5) | PT2425824T (de) |
RU (3) | RU2297225C2 (de) |
SI (5) | SI2425824T1 (de) |
TN (1) | TNSN04192A1 (de) |
TW (3) | TWI334779B (de) |
WO (2) | WO2003084504A2 (de) |
ZA (2) | ZA200407267B (de) |
Families Citing this family (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
KR100417489B1 (ko) | 1997-12-22 | 2004-02-05 | 유로-셀티크 소시에떼 아노뉨 | 오피오이드 효능제/길항제 혼합물 |
HU230828B1 (en) | 1999-10-29 | 2018-08-28 | Euro Celtique Sa | Controlled release hydrocodone formulations |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
DK1299104T3 (da) | 2000-02-08 | 2009-08-03 | Euro Celtique Sa | Orale opioidagonistformuleringer sikret mod forfalskning |
AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
WO2002036099A1 (en) | 2000-10-30 | 2002-05-10 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
US20030065002A1 (en) * | 2001-05-11 | 2003-04-03 | Endo Pharmaceuticals, Inc. | Abuse-resistant controlled-release opioid dosage form |
JP4256259B2 (ja) | 2001-07-18 | 2009-04-22 | ユーロ−セルティーク エス.エイ. | オキシコドン及びナロキソンの医薬配合物 |
AU2002323032B2 (en) | 2001-08-06 | 2005-02-24 | Euro-Celtique S.A. | Opioid agonist formulations with releasable and sequestered antagonist |
CA2708900C (en) | 2002-04-05 | 2019-06-04 | Purdue Pharma | Pharmaceutical preparation containing oxycodone and naloxone |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
PE20040134A1 (es) | 2002-07-25 | 2004-03-06 | Pharmacia Corp | Forma de dosificacion de una vez al dia de pramipexol |
MY135852A (en) | 2003-04-21 | 2008-07-31 | Euro Celtique Sa | Pharmaceutical products |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
CA2539027C (en) * | 2003-09-25 | 2010-02-23 | Euro-Celtique S.A. | Pharmaceutical combinations of hydrocodone and naltrexone |
TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
GB0403098D0 (en) | 2004-02-12 | 2004-03-17 | Euro Celtique Sa | Extrusion |
GB0501638D0 (en) * | 2005-01-28 | 2005-03-02 | Euro Celtique Sa | Particulates |
EP1604666A1 (de) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit |
EP1604667A1 (de) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioide zur Behandlung des Restless Leg Syndroms |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
KR20130003040A (ko) | 2004-08-13 | 2013-01-08 | 베링거 인겔하임 인터내셔날 게엠베하 | 프라미펙솔 또는 약제학적으로 허용되는 이의 염을 포함하는 연장 방출형 펠렛 제형, 이의 제조방법 및 이의 용도 |
DK1781260T4 (da) | 2004-08-13 | 2014-06-23 | Boehringer Ingelheim Int | Tabletformulering med forlænget frigivelse indeholdende pramipexol eller et farmaceutisk acceptabelt salt deraf, fremgangsmåde til fremstilling deraf og anvendelse deraf |
EP2319499A1 (de) | 2005-01-28 | 2011-05-11 | Euro-Celtique S.A. | Alkoholresistente Arzneiformen |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
EP1695700A1 (de) * | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Darreichungsform enthaltend Oxycodon und Naloxon |
EP1702558A1 (de) * | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Verfahren und Vorrichtung zur Darmtätigkeitserfassung |
EP1810678A1 (de) | 2006-01-19 | 2007-07-25 | Holger Lars Hermann | Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution |
AU2011202866B2 (en) * | 2006-01-27 | 2012-06-14 | Mundipharma Pty Limited | Tamper resistant dosage forms |
EP1813276A1 (de) * | 2006-01-27 | 2007-08-01 | Euro-Celtique S.A. | Manipulationssichere Dosierformen |
US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
DE202006018609U1 (de) * | 2006-08-29 | 2007-05-16 | Euro-Celtique S.A. | Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung |
EP1897543A1 (de) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine-Waffel zur Substitutionstherapie |
US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
US20080171762A1 (en) * | 2007-01-16 | 2008-07-17 | Ockert David M | Treatment of pain with naloxone |
DE102007011485A1 (de) * | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
CA2696341C (en) * | 2007-08-13 | 2016-05-17 | Abuse Deterrent Pharmaceutical Llc | Abuse resistant drugs, method of use and method of making |
RU2007137044A (ru) * | 2007-10-05 | 2009-04-10 | Общество С Ограниченной Ответственностью "Концерн О3" (Ru) | Лекарственное средство, обладающее гемопоэзстимулирующим и гепатопротекторным действием |
US20090142398A1 (en) * | 2007-11-21 | 2009-06-04 | Pharmascience Inc. | Novel pharmaceutical compositions comprising a disintegration matrix |
RU2493830C2 (ru) | 2008-01-25 | 2013-09-27 | Грюненталь Гмбх | Лекарственная форма |
AU2009243681B2 (en) | 2008-05-09 | 2013-12-19 | Grunenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
MY150600A (en) * | 2008-07-07 | 2014-01-30 | Euro Celtique Sa | Use of opioid antagonists for treating urinary retention |
JP2012501967A (ja) | 2008-08-20 | 2012-01-26 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 調節放出型多粒子のホットメルト押出成形 |
JP6216489B2 (ja) | 2008-10-30 | 2017-10-18 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 新規の、効力のあるタペンタドール剤形 |
BRPI0923836A2 (pt) | 2008-12-31 | 2015-07-21 | Upsher Smith Lab Inc | Composições farmacêuticas orais contendo opióide e métodos |
PT2405915T (pt) | 2009-03-10 | 2019-01-29 | Euro Celtique Sa | Composições farmacêuticas de libertação imediata compreendendo oxicodona e naloxona |
GB0909680D0 (en) | 2009-06-05 | 2009-07-22 | Euro Celtique Sa | Dosage form |
PL2456427T3 (pl) | 2009-07-22 | 2015-07-31 | Gruenenthal Gmbh | Wytłaczana na gorąco postać dawki o kontrolowanym uwalnianiu |
EP2997965B1 (de) | 2009-07-22 | 2019-01-02 | Grünenthal GmbH | Manipulationssichere darreichungsform für oxidationsempfindliche opioide |
CA2773521C (en) | 2009-09-17 | 2017-01-24 | Upsher-Smith Laboratories, Inc. | A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug |
US9125867B2 (en) * | 2010-02-24 | 2015-09-08 | Invincible Biotechnology | Diversion- and/or abuse-resistant compositions and methods for making the same |
TWI590835B (zh) | 2010-05-10 | 2017-07-11 | 歐 賽提克股份有限公司 | 含有氫嗎啡酮(hydromorphone)和納洛酮(naloxone)之藥學組成物 |
WO2011141489A1 (en) | 2010-05-10 | 2011-11-17 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
CA2798885C (en) | 2010-05-10 | 2014-11-18 | Euro-Celtique S.A. | Combination of active loaded granules with additional actives |
CA2798702A1 (en) | 2010-05-11 | 2011-11-17 | Cima Labs Inc. | Alcoholresistant metoprolol-containing extended-release oral dosage forms |
SG187713A1 (en) | 2010-08-04 | 2013-03-28 | Borody Thomas J | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
JP6007176B2 (ja) * | 2010-08-13 | 2016-10-12 | ユーロ−セルティーク エス.エイ. | 保存に安定な製剤を製造するための結合剤の使用 |
TWI516286B (zh) | 2010-09-02 | 2016-01-11 | 歌林達股份有限公司 | 含陰離子聚合物之抗破碎劑型 |
MX2013002377A (es) | 2010-09-02 | 2013-04-29 | Gruenenthal Gmbh | Forma de dosificacion resistente a manipulacion que comprende una sal inorganica. |
MY173890A (en) | 2010-09-30 | 2020-02-26 | Astrazeneca Ab | Crystalline naloxol-peg conjugate |
SG191145A1 (en) | 2010-12-13 | 2013-07-31 | Borody Thomas J | Gastric and colonic formulations and methods for making and using them |
CA2829385C (en) | 2011-03-09 | 2021-07-13 | Michael J. Sadowsky | Compositions and methods for transplantation of colon microbiota |
AT511581A1 (de) | 2011-05-26 | 2012-12-15 | G L Pharma Gmbh | Orale retardierende formulierung |
BR112014001091A2 (pt) | 2011-07-29 | 2017-02-14 | Gruenenthal Gmbh | comprimido resistente à adulteração que fornece liberação imediata do fármaco |
LT2736495T (lt) | 2011-07-29 | 2017-11-10 | Grünenthal GmbH | Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu |
CA2846420A1 (en) * | 2011-08-29 | 2013-03-07 | Dsm Ip Assets B.V. | Laboratory extruder |
PE20141171A1 (es) | 2011-10-06 | 2014-09-21 | Gruenenthal Chemie | Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioide |
JP6085307B2 (ja) | 2011-11-17 | 2017-02-22 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 薬理学的に活性な成分、オピオイドアンタゴニストおよび/または嫌忌剤(aversiveagent)、ポリアルキレンオキシドおよび陰イオン性ポリマーを含むタンパーレジスタント経口医薬剤形 |
BR112014019988A8 (pt) | 2012-02-28 | 2017-07-11 | Gruenenthal Gmbh | Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico |
AR092820A1 (es) | 2012-04-17 | 2015-05-06 | Purdue Pharma Lp | Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit |
AR090695A1 (es) | 2012-04-18 | 2014-12-03 | Gruenenthal Gmbh | Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
WO2013176774A1 (en) | 2012-05-25 | 2013-11-28 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
CN104540521A (zh) | 2012-06-04 | 2015-04-22 | 高拉夫·阿格拉沃尔 | 用于治疗克罗恩氏病和相关病况以及感染的组合物和方法 |
US10166219B2 (en) | 2012-07-27 | 2019-01-01 | Redhill Bipharma Ltd. | Formulations and methods of manufacturing formulations for use in colonic evacuation |
US10485798B2 (en) | 2012-08-22 | 2019-11-26 | Aptapharma Inc. | Methylnaltrexone nasal formulations, methods of making, and use thereof |
CN104981246A (zh) * | 2012-12-14 | 2015-10-14 | 特雷维治疗股份有限公司 | 治疗瘙痒的方法 |
US20140275149A1 (en) | 2013-03-15 | 2014-09-18 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
CA2910983C (en) | 2013-04-30 | 2021-11-02 | Thomas Julius Borody | Compositions and methods for treating microbiota-related psychotropic conditions and diseases |
CN105246897B (zh) | 2013-05-24 | 2017-12-26 | 罗德科技公司 | 阿片样缩酮化合物和其用途 |
JP6466417B2 (ja) | 2013-05-29 | 2019-02-06 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 二峰性放出プロファイルを有する改変防止(tamper−resistant)剤形 |
CA2907950A1 (en) | 2013-05-29 | 2014-12-04 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
MX368846B (es) | 2013-07-12 | 2019-10-18 | Gruenenthal Gmbh | Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo. |
MY183489A (en) | 2013-07-23 | 2021-02-22 | Euro Celtique Sa | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
WO2015023675A2 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US20150118300A1 (en) | 2013-10-31 | 2015-04-30 | Cima Labs Inc. | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
CN112716955A (zh) | 2013-11-13 | 2021-04-30 | 欧洲凯尔特公司 | 用于治疗疼痛和阿片样物质肠功能障碍综合征的氢吗啡酮和纳洛酮 |
CA2931553C (en) | 2013-11-26 | 2022-01-18 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
WO2015086528A1 (de) | 2013-12-11 | 2015-06-18 | Develco Pharma Schweiz Ag | Naloxon-monopräparat und mehrschichttablette |
US10105360B2 (en) | 2013-12-11 | 2018-10-23 | Develco Pharma Schweiz Ag | Method and composition for the treatment of opioid induced constipation |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
WO2015095644A1 (en) | 2013-12-20 | 2015-06-25 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
US9480644B2 (en) | 2014-03-14 | 2016-11-01 | Opiant Pharmaceuticals, Inc. | Nasal drug products and methods of their use |
CN110755372A (zh) | 2014-03-14 | 2020-02-07 | 欧皮安特制药有限公司 | 适于经鼻递送药物产品、用于鼻内给予的药用组合物及其用途 |
US10085937B2 (en) | 2014-03-14 | 2018-10-02 | Adapt Pharma Limited | Nasal drug products and methods of their use |
US9561177B2 (en) | 2014-03-14 | 2017-02-07 | Adapt Pharma Limited | Nasal drug products and methods of their use |
CA2947786A1 (en) | 2014-05-12 | 2015-11-19 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising tapentadol |
EP3148512A1 (de) | 2014-05-26 | 2017-04-05 | Grünenthal GmbH | Gegen entsorgung von ethanolischer dosis gesicherte mehrfachpartikel |
US9707184B2 (en) | 2014-07-17 | 2017-07-18 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
CN107205943A (zh) * | 2014-12-08 | 2017-09-26 | 德威洛克制药有限公司 | 纳洛酮单剂和多层片剂 |
EP3285745A1 (de) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Manipulationssichere darreichungsform mit sofortiger freisetzung und widerstand gegen lösungsmittelextraktion |
US9901603B2 (en) | 2015-05-14 | 2018-02-27 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and device for delivering them |
CN114470009A (zh) | 2015-05-22 | 2022-05-13 | 亚利桑那大学董事会 | 用于治疗自闭症谱系障碍及相关症状的方法 |
JP2018526414A (ja) | 2015-09-10 | 2018-09-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護 |
WO2017053327A1 (en) | 2015-09-24 | 2017-03-30 | San Diego State University (Sdsu) Foundation , Dba San Diego State University Research Foundation | Antibacterial and protective bacteriophage formulations and methods for making and using them |
US9943513B1 (en) | 2015-10-07 | 2018-04-17 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
US10624888B2 (en) * | 2016-03-31 | 2020-04-21 | SpecGx LLC | Extended release, abuse deterrent dosage forms |
US10335405B1 (en) | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
EP3290027A1 (de) * | 2016-09-02 | 2018-03-07 | Develco Pharma Schweiz AG | Verfahren und zusammensetzung zur behandlung von durch opioid induzierter verstopfung |
US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
US11026978B2 (en) | 2016-10-11 | 2021-06-08 | Finch Therapeutics Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
WO2018187464A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
JP2020513018A (ja) | 2017-04-05 | 2020-04-30 | クレストヴォ・ホールディングス・エルエルシー | パーキンソン病(pd)および関連する障害を治療するための組成物および方法 |
US11890306B2 (en) | 2017-05-26 | 2024-02-06 | Finch Therapeutics Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
AU2018313766A1 (en) | 2017-08-07 | 2020-02-20 | Finch Therapeutics, Inc. | Compositions and methods for maintaining and restoring a healthy gut barrier |
US10624856B2 (en) | 2018-01-31 | 2020-04-21 | Dharma Laboratories LLC | Non-extractable oral solid dosage forms |
WO2019152002A1 (en) * | 2018-01-31 | 2019-08-08 | Dharma Laboratories LLC | Non-extractable oral solid dosage forms |
WO2019165298A1 (en) | 2018-02-23 | 2019-08-29 | Rhodes Technologies | Novel opioid compounds and uses thereof |
US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
WO2020023486A1 (en) | 2018-07-23 | 2020-01-30 | Trevi Therapeutics, Inc. | Treatment of chronic cough, breathlessness and dyspnea |
CN113164527A (zh) | 2018-09-27 | 2021-07-23 | 芬奇治疗控股有限责任公司 | 用于治疗癫痫和相关障碍的组合物和方法 |
EP3965733A4 (de) | 2019-05-07 | 2023-01-11 | Clexio Biosciences Ltd. | Esketamin enthaltende missbrauchssichere darreichungsformen |
Family Cites Families (278)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2770569A (en) | 1952-08-01 | 1956-11-13 | Hoffmann La Roche | Analgesic compositions |
US3173877A (en) | 1957-09-09 | 1965-03-16 | Wyandotte Chemicals Corp | Detergent compositions comprising inorganic esters of epoxyhydrocarbon polymers |
US3173876A (en) * | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
NL271831A (de) * | 1960-11-29 | |||
US3493657A (en) | 1961-03-14 | 1970-02-03 | Mozes Juda Lewenstein | Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine |
US3332950A (en) | 1963-03-23 | 1967-07-25 | Endo Lab | 14-hydroxydihydronormorphinone derivatives |
US3276586A (en) * | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
NL6714885A (de) * | 1967-11-02 | 1969-05-06 | ||
US3541006A (en) * | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
US3541005A (en) * | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
US3773955A (en) | 1970-08-03 | 1973-11-20 | Bristol Myers Co | Analgetic compositions |
US3879555A (en) | 1970-11-16 | 1975-04-22 | Bristol Myers Co | Method of treating drug addicts |
US3676557A (en) | 1971-03-02 | 1972-07-11 | Endo Lab | Long-acting narcotic antagonist formulations |
GB1390772A (en) | 1971-05-07 | 1975-04-16 | Endo Lab | Oral narcotic composition |
FR2183546B1 (de) * | 1972-05-10 | 1975-06-20 | Servier Lab | |
US3965256A (en) | 1972-05-16 | 1976-06-22 | Synergistics | Slow release pharmaceutical compositions |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US3916889A (en) * | 1973-09-28 | 1975-11-04 | Sandoz Ag | Patient ventilator apparatus |
US3966940A (en) | 1973-11-09 | 1976-06-29 | Bristol-Myers Company | Analgetic compositions |
GB1478759A (en) * | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
US3966040A (en) * | 1975-03-05 | 1976-06-29 | Hazelwood John E | Combined vibratory feeder drive unit, vibratory feeder bowl, and parts separator |
US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4126684A (en) * | 1976-02-11 | 1978-11-21 | Ciba-Geigy Corporation | 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse |
US4063064A (en) * | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
LU77339A1 (de) | 1977-05-16 | 1979-01-19 | ||
US4176186A (en) | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
US4200098A (en) * | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
US4285987A (en) * | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
US4237140A (en) | 1979-05-18 | 1980-12-02 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and acetaminophen |
US4293539A (en) | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
IE49324B1 (en) | 1979-12-19 | 1985-09-18 | Euro Celtique Sa | Controlled release compositions |
US4457933A (en) * | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
US4401672A (en) | 1981-10-13 | 1983-08-30 | Regents Of The University Of Minnesota | Non-addictive narcotic antitussive preparation |
US4608376A (en) | 1981-10-16 | 1986-08-26 | Carolyn McGinnis | Opiate agonists and antagonists |
US4987136A (en) | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
DE3381877D1 (de) | 1982-03-16 | 1990-10-18 | Univ Rockefeller | Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler stoerungen. |
US4443428A (en) | 1982-06-21 | 1984-04-17 | Euroceltique, S.A. | Extended action controlled release compositions |
US4451470A (en) | 1982-07-06 | 1984-05-29 | E. I. Du Pont De Nemours And Company | Analgesic, antagonist, and/or anorectic 14-fluoromorphinans |
US4803208A (en) | 1982-09-30 | 1989-02-07 | Sloan-Kettering Institute For Cancer Research | Opiate agonists and antagonists |
GB8332556D0 (en) | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US5266574A (en) | 1984-04-09 | 1993-11-30 | Ian S. Zagon | Growth regulation and related applications of opioid antagonists |
US4668685A (en) * | 1984-07-05 | 1987-05-26 | E.I. Du Pont De Nemours And Company | Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists |
US4626539A (en) * | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
DE3434946A1 (de) | 1984-09-22 | 1986-04-03 | Basf Ag, 6700 Ludwigshafen | Diarylacetylene, ihre herstellung und verwendung |
US4573995A (en) | 1984-10-09 | 1986-03-04 | Alza Corporation | Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine |
GB8430346D0 (en) | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
ZA861211B (en) | 1985-02-25 | 1987-10-28 | Lilly Co Eli | Analgesic composition |
US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
JPS61280423A (ja) | 1985-06-05 | 1986-12-11 | Kiyuukiyuu Yakuhin Kogyo Kk | 口腔内粘膜貼付剤 |
GB8514665D0 (en) | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
FR2585246A1 (fr) | 1985-07-26 | 1987-01-30 | Cortial | Procede d'obtention de formes pharmaceutiques solides a liberation prolongee |
GB8521350D0 (en) | 1985-08-28 | 1985-10-02 | Euro Celtique Sa | Analgesic composition |
EP0236477B1 (de) | 1985-09-06 | 1993-01-20 | Baker Norton Pharmaceuticals, Inc. | Verwendung von 6-Methylen-6-desoxy-N-cyclopropylmethyl-14-hydroxydihydronormorphin |
US4889860A (en) | 1985-09-23 | 1989-12-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
US4760069A (en) | 1985-09-23 | 1988-07-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
US4722928A (en) | 1985-12-02 | 1988-02-02 | E. I. Du Pont De Nemours And Company | N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes |
US4730048A (en) | 1985-12-12 | 1988-03-08 | Regents Of The University Of Minnesota | Gut-selective opiates |
US4861781A (en) | 1986-03-07 | 1989-08-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US4719215A (en) | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US5316759A (en) | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
GB8613688D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB8613689D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
ATE107857T1 (de) | 1986-06-10 | 1994-07-15 | Euro Celtique Sa | Zusammensetzung mit kontrollierter freisetzung von dihydrocodein. |
US4769372A (en) | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4785000A (en) | 1986-06-18 | 1988-11-15 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4861598A (en) * | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US4970075A (en) | 1986-07-18 | 1990-11-13 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US5356900A (en) | 1986-10-07 | 1994-10-18 | Bernard Bihari | Method of treating chronic herpes virus infections using an opiate receptor antagonist |
GB8626098D0 (en) | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
US4806543A (en) | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
GB8628728D0 (en) | 1986-12-02 | 1987-01-07 | Euro Celtique Sa | Spheroids |
GB8705083D0 (en) | 1987-03-04 | 1987-04-08 | Euro Celtique Sa | Spheroids |
GB8728294D0 (en) | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
DE3812567A1 (de) * | 1988-04-15 | 1989-10-26 | Basf Ag | Verfahren zur herstellung pharmazeutischer mischungen |
US4873076A (en) | 1988-04-29 | 1989-10-10 | Baker Cummins Pharmaceuticals, Inc. | Method of safely providing anesthesia or conscious sedation |
GB8813064D0 (en) | 1988-06-02 | 1988-07-06 | Euro Celtique Sa | Controlled release dosage forms having defined water content |
US4882335A (en) | 1988-06-13 | 1989-11-21 | Alko Limited | Method for treating alcohol-drinking response |
EP0352361A1 (de) | 1988-07-29 | 1990-01-31 | The Rockefeller University | Verfahren zur Behandlung von Patienten die an chronischen Schmerzen oder chronischem Husten leiden |
US5236714A (en) | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
CA2002492A1 (en) | 1988-11-11 | 1990-05-11 | Sandra T. A. Malkowska | Pharmaceutical ion exchange resin composition |
US5102887A (en) | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
US5096715A (en) | 1989-11-20 | 1992-03-17 | Alko Ltd. | Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist |
US5075341A (en) | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
US5086058A (en) | 1990-06-04 | 1992-02-04 | Alko Ltd. | Method for treating alcoholism with nalmefene |
FR2669336B1 (fr) | 1990-11-20 | 1993-01-22 | Adir | Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
HU208633B (en) | 1991-02-04 | 1993-12-28 | Alkaloida Vegyeszeti Gyar | Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression |
US5486362A (en) | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
JP3178541B2 (ja) | 1991-05-29 | 2001-06-18 | キヤノン株式会社 | 画像処理方法及び装置 |
US5149538A (en) | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
GB9117361D0 (en) * | 1991-08-12 | 1991-09-25 | Euro Celtique Sa | Oral dosage form |
KR100221695B1 (ko) | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | 약학적 구상 제형 |
DE122004000032I2 (de) | 1991-09-06 | 2006-02-09 | Mcneilab Inc | Zusammensetzung die eine Tramadol-Verbindung und Acetaminophen enth{lt, und ihre Verwendung |
US5215758A (en) | 1991-09-11 | 1993-06-01 | Euroceltique, S.A. | Controlled release matrix suppository for pharmaceuticals |
US5225440A (en) | 1991-09-13 | 1993-07-06 | The United States Of America As Represented By The Department Of Health And Human Services | Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase |
US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5656295A (en) * | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
US5472712A (en) * | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5681585A (en) * | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5273760A (en) * | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5958459A (en) | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
GB9203689D0 (en) | 1992-02-20 | 1992-04-08 | Euro Celtique Sa | Pharmaceutical composition |
GB9204354D0 (en) | 1992-02-28 | 1992-04-08 | Biokine Tech Ltd | Compounds for medicinal use |
PT647137E (pt) | 1992-06-22 | 2008-11-24 | Univ California | Antagonistas dos receptores da glicina e a sua utilização |
US5352680A (en) | 1992-07-15 | 1994-10-04 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists to block opioid agonist tolerance and dependence |
US5256669A (en) | 1992-08-07 | 1993-10-26 | Aminotek Sciences, Inc. | Methods and compositions for treating acute or chronic pain and drug addiction |
US5324351A (en) * | 1992-08-13 | 1994-06-28 | Euroceltique | Aqueous dispersions of zein and preparation thereof |
US5633259A (en) | 1992-09-21 | 1997-05-27 | United Biomedical, Inc. | Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction |
US5472943A (en) | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
US5512578A (en) | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
US5580876A (en) | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
CA2145207A1 (en) | 1992-09-21 | 1994-03-22 | Bo-Yi Qin | Methods for identifying and using low/non-addictive opioid analgesics |
US6096756A (en) | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US20010006967A1 (en) | 1992-09-21 | 2001-07-05 | Stanley M. Crain | Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists |
US5869097A (en) | 1992-11-02 | 1999-02-09 | Alza Corporation | Method of therapy comprising an osmotic caplet |
US5604260A (en) | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
US5321012A (en) | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
US5585348A (en) | 1993-02-10 | 1996-12-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia |
CA2115792C (en) | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
US5352683A (en) | 1993-03-05 | 1994-10-04 | Virginia Commonwealth University Medical College Of Virginia | Method for the treatment of chronic pain |
US5409944A (en) | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
IL119660A (en) | 1993-05-10 | 2002-09-12 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
US5457208A (en) | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
US5436265A (en) | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
NZ260883A (en) | 1993-07-01 | 1997-06-24 | Euro Celtique Sa | Oral sustained-release medicaments containing morphine |
CN1230154C (zh) * | 1993-07-01 | 2005-12-07 | 欧洲凯尔特公司 | 缓释组合物及制备药用组合物的方法 |
US5879705A (en) | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
DE4325465B4 (de) * | 1993-07-29 | 2004-03-04 | Zenz, Michael, Prof. Dr.med. | Orales pharmazeutisches Präparat für die Schmerztherapie |
GB9319568D0 (en) | 1993-09-22 | 1993-11-10 | Euro Celtique Sa | Pharmaceutical compositions and usages |
EP0647448A1 (de) | 1993-10-07 | 1995-04-12 | Euroceltique S.A. | Oral verabreichbare, Opioid-Analgetika enthaltende Arzneimittel mit verlängerter Wirkung |
DK0654263T3 (da) | 1993-11-23 | 2002-04-29 | Euro Celtique Sa | Fremgangsmåde til fremstilling af et præparat med langvarig frigivelse |
KR100354702B1 (ko) | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | 약학조성물의제조방법및서방형조성물 |
US6210714B1 (en) | 1993-11-23 | 2001-04-03 | Euro-Celtique S.A. | Immediate release tablet cores of acetaminophen having sustained-release coating |
US5891471A (en) | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
US5500227A (en) | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
US5834477A (en) | 1993-12-08 | 1998-11-10 | The United States Of America As Represented By The Secretary Of The Army | Opiate analgesic formulation with improved safety |
US5376662A (en) | 1993-12-08 | 1994-12-27 | Ockert; David M. | Method of attenuating nerve injury induced pain |
US5843480A (en) | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
US6077533A (en) | 1994-05-25 | 2000-06-20 | Purdue Pharma L.P. | Powder-layered oral dosage forms |
US5411745A (en) * | 1994-05-25 | 1995-05-02 | Euro-Celtique, S.A. | Powder-layered morphine sulfate formulations |
US5958458A (en) * | 1994-06-15 | 1999-09-28 | Dumex-Alpharma A/S | Pharmaceutical multiple unit particulate formulation in the form of coated cores |
US5460826A (en) | 1994-06-27 | 1995-10-24 | Alza Corporation | Morphine therapy |
GB9414699D0 (en) | 1994-07-21 | 1994-09-07 | Slagel David | Aqueous foamable composition |
US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US5593994A (en) | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
US5866154A (en) * | 1994-10-07 | 1999-02-02 | The Dupont Merck Pharmaceutical Company | Stabilized naloxone formulations |
GB9422154D0 (en) | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
CN1160115C (zh) | 1994-12-12 | 2004-08-04 | 奥默罗斯公司 | 用于抑制疼痛,炎症和痉挛的冲洗液和方法 |
GB9426102D0 (en) | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Pharmacuetical compositions |
US5692500A (en) | 1995-01-09 | 1997-12-02 | Gaston-Johansson; Fannie | Pain measurement and recording tool and method |
US5552422A (en) | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
US5578725A (en) | 1995-01-30 | 1996-11-26 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists |
US20020006964A1 (en) * | 1995-05-16 | 2002-01-17 | Young James W. | Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds |
US5639780A (en) | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
US5510368A (en) | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
US5604253A (en) | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
AU706541B2 (en) | 1995-06-09 | 1999-06-17 | Euro-Celtique S.A. | Formulations and methods for providing prolonged local anesthesia |
US5931809A (en) | 1995-07-14 | 1999-08-03 | Depotech Corporation | Epidural administration of therapeutic compounds with sustained rate of release |
GB9517062D0 (en) * | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
GB9517883D0 (en) | 1995-09-01 | 1995-11-01 | Euro Celtique Sa | Improved pharmaceutical ion exchange resin composition |
GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
US5811126A (en) | 1995-10-02 | 1998-09-22 | Euro-Celtique, S.A. | Controlled release matrix for pharmaceuticals |
AUPN603895A0 (en) | 1995-10-19 | 1995-11-09 | University Of Queensland, The | Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids |
AU1128297A (en) | 1995-12-06 | 1997-06-27 | Eli Lilly And Company | Composition for treating pain |
DK0888111T3 (da) | 1996-03-08 | 2003-09-22 | Nycomed Danmark As | Modified-release-dosispræparat med multiple enheder |
DK0914097T3 (da) | 1996-03-12 | 2002-04-29 | Alza Corp | Sammensætning og doseringsform omfattende opioid antagonist |
US6103258A (en) | 1996-04-12 | 2000-08-15 | Simon; David Lew | Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics |
EP0854884A1 (de) * | 1996-04-17 | 1998-07-29 | Neurocrine Biosciences, Inc. | Inhibitoren von liganden der insulin-ähnlichen faktor bindenden proteine und methoden für ihre verwendung |
WO1997045091A2 (en) * | 1996-05-31 | 1997-12-04 | Euro-Celtique, S.A. | Sustained release oxycodone formulations with no fed/fast effect |
WO1998024412A2 (en) * | 1996-12-05 | 1998-06-11 | The Board Of Trustees Of The University Of Illinois | Compounds useful against diseases of the colon and methods for orally administering same |
DE19651551C2 (de) | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioidantagonisthaltige galenische Formulierung |
DE29719704U1 (de) | 1997-02-14 | 1998-01-22 | Goedecke Ag | Stabile Zubereitungen von Naloxonhydrochlorid |
DE59800046D1 (de) | 1997-02-14 | 1999-12-23 | Goedecke Ag | Stabilisierung von naloxonhydrochlorid |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
DE19710008A1 (de) | 1997-03-12 | 1998-09-17 | Basf Ag | Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung |
US5780479A (en) | 1997-04-04 | 1998-07-14 | Regents Of The University Of Minnesota | Use of opioid antagonists to treat impulse-control disorders |
US6207142B1 (en) * | 1997-04-14 | 2001-03-27 | Janssen Pharmaceutica N.V. | Compositions containing an antifungal and a cationic agent |
ATE322892T1 (de) | 1997-07-02 | 2006-04-15 | Euro Celtique Sa | Stabilisierte tramadol formulierungen mit verzögerter freisetzung |
WO1999005960A1 (en) | 1997-07-30 | 1999-02-11 | Universite De Montreal | Portable and programmable interactive visual analogue scale data-logger device |
ATE510542T1 (de) | 1997-09-04 | 2011-06-15 | Novoneuron Inc | Noribogain zur behandlung von schmerzen und drogenabhängigkeit |
US5972954A (en) | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
US6274591B1 (en) | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
ATE210983T1 (de) | 1997-11-03 | 2002-01-15 | Stada Arzneimittel Ag | Stabilisiertes kombinationsarzneimittel enthaltend naloxone und ein opiatanalgetikum |
US6228863B1 (en) | 1997-12-22 | 2001-05-08 | Euro-Celtique S.A. | Method of preventing abuse of opioid dosage forms |
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
KR100417489B1 (ko) | 1997-12-22 | 2004-02-05 | 유로-셀티크 소시에떼 아노뉨 | 오피오이드 효능제/길항제 혼합물 |
BR9908953A (pt) * | 1998-03-27 | 2000-12-05 | Upjohn Co | Utilização de cabergolina no tratamento da sìndrome de pernas agitadas (sìndrome de ekbom) |
US5957459A (en) | 1998-04-27 | 1999-09-28 | Chae; Myung Joo | Banking card game |
ATE261302T1 (de) | 1998-05-28 | 2004-03-15 | Krewel Meuselbach Gmbh | Retardiertes schmerzmittel enthaltend tilidin |
DE19857766A1 (de) | 1998-05-28 | 1999-12-02 | Krewel Meuselbach Gmbh | Retardiertes Schmerzmittel enthaltend Tilidin |
DE29818454U1 (de) | 1998-10-15 | 1999-01-14 | Euro Celtique Sa | Opioid-Analgetikum |
SE9803760D0 (sv) | 1998-11-04 | 1998-11-04 | Jan Hedner | Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel |
FR2787715B1 (fr) | 1998-12-23 | 2002-05-10 | Synthelabo | Composition pharmaceutique comprenant un compose hypnotique ou un de ses sels pharmaceutiquement acceptables |
DE19859636A1 (de) * | 1998-12-23 | 2000-06-29 | Hexal Ag | Kontrolliert freisetzende pharmazeutische Zusammensetzung mit Tilidinmesylat als Wirkstoff |
DE19901085C2 (de) | 1999-01-14 | 2003-12-18 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit einer selbstklebenden Matrix, enthaltend organische Säure-Additionssalze von Alkaloiden des Morphin- bzw. Morphinantyps |
US6194382B1 (en) | 1999-03-03 | 2001-02-27 | Albert Einstein College Of Medicine Of Yeshiva University | Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists |
DE19918325A1 (de) | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion |
US6765010B2 (en) | 1999-05-06 | 2004-07-20 | Pain Therapeutics, Inc. | Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
US20030178031A1 (en) * | 1999-05-07 | 2003-09-25 | Du Pen, Inc. | Method for cancer pain treatment |
US6419595B1 (en) | 1999-07-09 | 2002-07-16 | Bridgestone Sports Co., Ltd. | Solid golf ball |
US6451007B1 (en) | 1999-07-29 | 2002-09-17 | Dale E. Koop | Thermal quenching of tissue |
US20030118641A1 (en) * | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
DE19938823A1 (de) | 1999-08-19 | 2001-02-22 | Boehringer Ingelheim Pharma | Medikamentöse Behandlung des Restless Leg Syndroms |
US6258042B1 (en) * | 1999-09-17 | 2001-07-10 | James S. Factor | Visual analog scale and method of use for the diagnosis and/or treatment of physical pain |
US6451806B2 (en) | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
PT1225897E (pt) * | 1999-11-01 | 2005-01-31 | John Rhodes | Composicao para o tratamento da obstipacao e do sindroma do intestino irritavel |
EP1244447B1 (de) | 1999-11-29 | 2007-01-10 | Adolor Corporation | Neue verfahren und zubereitungen die opioiden und deren antagonisten enthalten |
WO2001052851A1 (en) | 2000-01-22 | 2001-07-26 | Albert Shulman | Methods for the treatment of substance abuse |
DK1299104T3 (da) | 2000-02-08 | 2009-08-03 | Euro Celtique Sa | Orale opioidagonistformuleringer sikret mod forfalskning |
US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
AU4743601A (en) | 2000-03-15 | 2001-09-24 | Wolfgang Sadee | Neutral antagonists and use thereof in treating drug abuse |
JP2004501094A (ja) | 2000-05-05 | 2004-01-15 | ペイン・セラピューティクス・インコーポレイテッド | オピオイドアゴニストの効力を増強するか、またはオピオイドアゴニストの有害な副作用を減弱するための新規な組成物および方法 |
EP1284736A2 (de) | 2000-05-05 | 2003-02-26 | Pain Therapeutics, Inc. | Opioidantagonisthaltige zusammensetzung und dosierungsformen |
US6525062B2 (en) | 2000-06-09 | 2003-02-25 | The Regents Of The University Of California | Method of treating pain using nalbuphine and opioid antagonists |
US7223421B2 (en) * | 2000-06-30 | 2007-05-29 | Mcneil-Ppc, Inc. | Teste masked pharmaceutical particles |
GB0026137D0 (en) | 2000-10-25 | 2000-12-13 | Euro Celtique Sa | Transdermal dosage form |
AR031152A1 (es) * | 2000-10-31 | 2003-09-10 | Upjohn Co | Tratamientos nuevos para el sindrome de piernas inquietas |
WO2002085839A1 (en) * | 2001-04-19 | 2002-10-31 | Warner-Lambert Company Llc | Fused bicyclic or tricyclic amino acids |
UA81224C2 (uk) | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
DE60216078T2 (de) * | 2001-05-11 | 2007-07-05 | Endo Pharmaceuticals Inc. | Opioid enthaltende arzneiform gegen missbrauch |
US20030065002A1 (en) * | 2001-05-11 | 2003-04-03 | Endo Pharmaceuticals, Inc. | Abuse-resistant controlled-release opioid dosage form |
DE10131113A1 (de) | 2001-06-28 | 2003-01-23 | Siemens Linear Motor Systems G | Rotations-Elektromotor |
WO2003004009A1 (en) | 2001-07-02 | 2003-01-16 | Geneva Pharmaceuticals, Inc. | Pharmaceutical composition |
JP4256259B2 (ja) * | 2001-07-18 | 2009-04-22 | ユーロ−セルティーク エス.エイ. | オキシコドン及びナロキソンの医薬配合物 |
US20030157168A1 (en) | 2001-08-06 | 2003-08-21 | Christopher Breder | Sequestered antagonist formulations |
US7332182B2 (en) * | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
HUP0401344A2 (hu) | 2001-08-06 | 2004-11-29 | Euro-Celtique S.A. | Gyógyszerkészítmények opioidokkal való visszaélés megakadályozására, és eljárás előállításukra |
BR0212019A (pt) | 2001-08-06 | 2005-08-09 | Euro Celtique Sa | Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem |
US20030044458A1 (en) * | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
AU2002323032B2 (en) | 2001-08-06 | 2005-02-24 | Euro-Celtique S.A. | Opioid agonist formulations with releasable and sequestered antagonist |
US7144587B2 (en) * | 2001-08-06 | 2006-12-05 | Euro-Celtique S.A. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
ATE426429T1 (de) | 2001-09-06 | 2009-04-15 | Hans Gregersen | Ballonkathetersystem zur stimulation und messung der durch stimuli erzeugten reaktion |
WO2003024429A1 (en) * | 2001-09-21 | 2003-03-27 | Egalet A/S | Polymer release system |
US20040253310A1 (en) * | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
CA2461539A1 (en) * | 2001-09-24 | 2003-04-03 | Faruk S. Abuzzahab, Sr. | Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder |
WO2003073937A1 (en) | 2002-03-06 | 2003-09-12 | Euro-Celtique S.A. | Analog scale for measuring pain |
AU2003220290B2 (en) | 2002-03-14 | 2007-06-14 | Euro-Celtique S.A. | Naltrexone hydrochloride compositions |
CA2708900C (en) | 2002-04-05 | 2019-06-04 | Purdue Pharma | Pharmaceutical preparation containing oxycodone and naloxone |
DE10215131A1 (de) | 2002-04-05 | 2003-10-16 | Euro Celtique Sa | Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen |
DE10215067A1 (de) | 2002-04-05 | 2003-10-16 | Euro Celtique Sa | Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst |
US20030191147A1 (en) * | 2002-04-09 | 2003-10-09 | Barry Sherman | Opioid antagonist compositions and dosage forms |
EP1364649A1 (de) | 2002-05-23 | 2003-11-26 | Cilag AG | Topirimat-Tramadol Addukt und seine Verwendung |
CA2491572C (en) * | 2002-07-05 | 2010-03-23 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
RU2222260C1 (ru) | 2002-07-08 | 2004-01-27 | Сибирский государственный медицинский университет | Способ дифференцированной оценки степени функциональной активности тонкой кишки |
CA2499994C (en) | 2002-09-23 | 2012-07-10 | Verion, Inc. | Abuse-resistant pharmaceutical compositions |
JP2006516969A (ja) | 2003-01-23 | 2006-07-13 | アモレパシフィック コーポレーション | 徐放性製剤及びその製造方法 |
US20040266806A1 (en) | 2003-04-08 | 2004-12-30 | Sanghvi Suketu P. | Pharmaceutical formulation |
TWI357815B (en) | 2003-06-27 | 2012-02-11 | Euro Celtique Sa | Multiparticulates |
US20050053659A1 (en) | 2003-09-10 | 2005-03-10 | Pace Gary W. | Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness |
TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
US7700626B2 (en) * | 2004-06-04 | 2010-04-20 | Adolor Corporation | Compositions containing opioid antagonists |
EP1604667A1 (de) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioide zur Behandlung des Restless Leg Syndroms |
EP1604666A1 (de) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit |
GB2418854B (en) | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
EP2319499A1 (de) | 2005-01-28 | 2011-05-11 | Euro-Celtique S.A. | Alkoholresistente Arzneiformen |
EP1695700A1 (de) * | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Darreichungsform enthaltend Oxycodon und Naloxon |
EP1702558A1 (de) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Verfahren und Vorrichtung zur Darmtätigkeitserfassung |
US20070092576A1 (en) | 2005-10-20 | 2007-04-26 | Adolor Corporation | Compositions containing opioid antagonists |
EP1813276A1 (de) | 2006-01-27 | 2007-08-01 | Euro-Celtique S.A. | Manipulationssichere Dosierformen |
US20070185145A1 (en) | 2006-02-03 | 2007-08-09 | Royds Robert B | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same |
WO2007111945A2 (en) | 2006-03-22 | 2007-10-04 | Trustees Of Boston University | Method for management of diarrhea |
US7879870B2 (en) | 2006-04-19 | 2011-02-01 | Smith Jill P | Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists |
DE202006018609U1 (de) | 2006-08-29 | 2007-05-16 | Euro-Celtique S.A. | Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung |
TW200817048A (en) | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
EP2042176A1 (de) | 2007-09-26 | 2009-04-01 | Euro-Celtique S.A. | Verwendung einer Kombination aus einem Opioidagonisten und Opioidantagonisten für die Behandlung von Morbus Crohn |
MY150600A (en) | 2008-07-07 | 2014-01-30 | Euro Celtique Sa | Use of opioid antagonists for treating urinary retention |
PT2405915T (pt) | 2009-03-10 | 2019-01-29 | Euro Celtique Sa | Composições farmacêuticas de libertação imediata compreendendo oxicodona e naloxona |
NO330672B1 (no) | 2009-11-12 | 2011-06-06 | Proxdynamics As | Rotormekanisme for helikoptere |
JP6007176B2 (ja) | 2010-08-13 | 2016-10-12 | ユーロ−セルティーク エス.エイ. | 保存に安定な製剤を製造するための結合剤の使用 |
-
2003
- 2003-04-04 CA CA2708900A patent/CA2708900C/en not_active Expired - Fee Related
- 2003-04-04 DE DE17169621.4T patent/DE17169621T1/de active Pending
- 2003-04-04 DK DK03720425.2T patent/DK1492506T4/en active
- 2003-04-04 ES ES11177518.5T patent/ES2627300T3/es not_active Expired - Lifetime
- 2003-04-04 EP EP10180496A patent/EP2316428A1/de not_active Withdrawn
- 2003-04-04 CN CN2012102169087A patent/CN102813654A/zh active Pending
- 2003-04-04 EP EP10176078A patent/EP2308475A1/de not_active Withdrawn
- 2003-04-04 GE GEAP8488A patent/GEP20064022B/en unknown
- 2003-04-04 PT PT111775169T patent/PT2425824T/pt unknown
- 2003-04-04 GE GEAP20038488A patent/GEP20074022B/en unknown
- 2003-04-04 CA CA2478515A patent/CA2478515C/en not_active Expired - Lifetime
- 2003-04-04 SI SI200332523A patent/SI2425824T1/sl unknown
- 2003-04-04 EP EP05020580A patent/EP1639997A1/de not_active Withdrawn
- 2003-04-04 ES ES17154462T patent/ES2733051T1/es active Pending
- 2003-04-04 HU HUE11177516A patent/HUE032656T2/en unknown
- 2003-04-04 ES ES03720425.2T patent/ES2320748T5/es not_active Expired - Lifetime
- 2003-04-04 US US10/510,673 patent/US20050245483A1/en not_active Abandoned
- 2003-04-04 DK DK11177520.1T patent/DK2425825T3/en active
- 2003-04-04 IL IL16399003A patent/IL163990A0/xx unknown
- 2003-04-04 HU HUE11177518A patent/HUE032529T2/en unknown
- 2003-04-04 SI SI200332440T patent/SI1492505T1/sl unknown
- 2003-04-04 EP EP20100176720 patent/EP2319496A1/de not_active Withdrawn
- 2003-04-04 LT LTEP11177520.1T patent/LT2425825T/lt unknown
- 2003-04-04 AU AU2003224041A patent/AU2003224041B2/en not_active Expired
- 2003-04-04 EP EP03720424.5A patent/EP1492505B1/de not_active Revoked
- 2003-04-04 TW TW092107765A patent/TWI334779B/zh not_active IP Right Cessation
- 2003-04-04 PT PT111775185T patent/PT2425821T/pt unknown
- 2003-04-04 DK DK11177518.5T patent/DK2425821T5/en active
- 2003-04-04 EP EP10180498A patent/EP2316429A1/de not_active Withdrawn
- 2003-04-04 KR KR1020067027164A patent/KR100784341B1/ko active IP Right Grant
- 2003-04-04 SI SI200332524A patent/SI2425821T1/sl unknown
- 2003-04-04 EP EP17154462.0A patent/EP3241548A1/de not_active Withdrawn
- 2003-04-04 HU HUE11177520A patent/HUE031668T2/en unknown
- 2003-04-04 BR BR0309004-3A patent/BR0309004A/pt not_active Application Discontinuation
- 2003-04-04 BR BRPI0309544A patent/BRPI0309544B8/pt not_active IP Right Cessation
- 2003-04-04 AU AU2003224040A patent/AU2003224040B2/en not_active Expired
- 2003-04-04 PT PT111775201T patent/PT2425825T/pt unknown
- 2003-04-04 JP JP2003581744A patent/JP4620355B2/ja not_active Expired - Fee Related
- 2003-04-04 EP EP03720425.2A patent/EP1492506B2/de not_active Expired - Lifetime
- 2003-04-04 ES ES03720424.5T patent/ES2546010T3/es not_active Expired - Lifetime
- 2003-04-04 EP EP11177520.1A patent/EP2425825B9/de not_active Revoked
- 2003-04-04 EP EP11177516.9A patent/EP2425824B1/de not_active Revoked
- 2003-04-04 TW TW095133492A patent/TWI345973B/zh not_active IP Right Cessation
- 2003-04-04 RU RU2004130845/15A patent/RU2297225C2/ru active
- 2003-04-04 MX MXPA04009713A patent/MXPA04009713A/es active IP Right Grant
- 2003-04-04 CN CN201710521042.3A patent/CN107669681A/zh active Pending
- 2003-04-04 ES ES17169621T patent/ES2733044T1/es active Pending
- 2003-04-04 AT AT03720425T patent/ATE418967T2/de active
- 2003-04-04 LT LTEP11177516.9T patent/LT2425824T/lt unknown
- 2003-04-04 EP EP10180494A patent/EP2311438A1/de not_active Withdrawn
- 2003-04-04 WO PCT/EP2003/003541 patent/WO2003084504A2/en active Application Filing
- 2003-04-04 CA CA002478523A patent/CA2478523A1/en not_active Abandoned
- 2003-04-04 EP EP11177513A patent/EP2425823A1/de not_active Withdrawn
- 2003-04-04 SI SI200331518T patent/SI1492506T1/sl unknown
- 2003-04-04 EP EP11177518.5A patent/EP2425821B1/de not_active Revoked
- 2003-04-04 DE DE20308437U patent/DE20308437U1/de not_active Expired - Lifetime
- 2003-04-04 EP EP10180495A patent/EP2308474A1/de not_active Withdrawn
- 2003-04-04 HU HUE03720424A patent/HUE027004T2/en unknown
- 2003-04-04 DK DK11177516.9T patent/DK2425824T5/en active
- 2003-04-04 AP APAP/P/2004/003138A patent/AP2397A/en active
- 2003-04-04 AP APAP/P/2004/003137A patent/AP2043A/en active
- 2003-04-04 NZ NZ535286A patent/NZ535286A/en not_active IP Right Cessation
- 2003-04-04 KR KR10-2004-7015828A patent/KR20040098050A/ko not_active Application Discontinuation
- 2003-04-04 TW TW092107773A patent/TWI337077B/zh not_active IP Right Cessation
- 2003-04-04 ES ES11177516.9T patent/ES2627298T3/es not_active Expired - Lifetime
- 2003-04-04 DK DK03720424.5T patent/DK1492505T3/en active
- 2003-04-04 PT PT03720425T patent/PT1492506E/pt unknown
- 2003-04-04 GE GEAP8489A patent/GEP20084485B/en unknown
- 2003-04-04 MX MXPA04009714A patent/MXPA04009714A/es active IP Right Grant
- 2003-04-04 PT PT37204245T patent/PT1492505E/pt unknown
- 2003-04-04 EP EP10160827A patent/EP2243471A1/de not_active Withdrawn
- 2003-04-04 DE DE60325567T patent/DE60325567D1/de not_active Expired - Lifetime
- 2003-04-04 US US10/510,674 patent/US20050245556A1/en not_active Abandoned
- 2003-04-04 DE DE17154462.0T patent/DE17154462T1/de active Pending
- 2003-04-04 JP JP2003581760A patent/JP4755810B2/ja not_active Expired - Fee Related
- 2003-04-04 DE DE20321531U patent/DE20321531U1/de not_active Expired - Lifetime
- 2003-04-04 DE DE20308436U patent/DE20308436U1/de not_active Expired - Lifetime
- 2003-04-04 EP EP17169621.4A patent/EP3326618A1/de not_active Withdrawn
- 2003-04-04 SI SI200332513A patent/SI2425825T1/sl unknown
- 2003-04-04 CN CN038077965A patent/CN1646102B/zh not_active Expired - Lifetime
- 2003-04-04 CN CNB038071770A patent/CN100411611C/zh not_active Expired - Lifetime
- 2003-04-04 WO PCT/EP2003/003540 patent/WO2003084520A2/en active Application Filing
- 2003-04-04 RU RU2004131870/15A patent/RU2295344C2/ru active
- 2003-04-04 EP EP05020579A patent/EP1639996A1/de not_active Withdrawn
- 2003-04-04 KR KR1020047015830A patent/KR100717591B1/ko active IP Right Grant
- 2003-04-04 ES ES11177520.1T patent/ES2608006T3/es not_active Expired - Lifetime
- 2003-04-04 LT LTEP11177518.5T patent/LT2425821T/lt unknown
- 2003-04-07 AR ARP030101200A patent/AR039378A1/es not_active Application Discontinuation
- 2003-04-07 AR ARP030101201A patent/AR039379A1/es not_active Application Discontinuation
-
2004
- 2004-09-09 IL IL163990A patent/IL163990A/en active IP Right Grant
- 2004-09-09 IL IL16398904A patent/IL163989A0/xx unknown
- 2004-09-10 ZA ZA2004/07267A patent/ZA200407267B/en unknown
- 2004-09-13 ZA ZA2004/07317A patent/ZA200407317B/en unknown
- 2004-09-23 CO CO04094961A patent/CO5611100A2/es not_active Application Discontinuation
- 2004-09-24 CO CO04095278A patent/CO5611093A2/es not_active Application Discontinuation
- 2004-10-04 TN TNP2004000192A patent/TNSN04192A1/fr unknown
- 2004-11-03 MA MA27929A patent/MA27116A1/fr unknown
- 2004-11-03 MA MA27928A patent/MA27249A1/fr unknown
-
2005
- 2005-06-15 HK HK05105024.4A patent/HK1072366A1/xx not_active IP Right Cessation
- 2005-06-15 HK HK05105025.3A patent/HK1072367A1/xx not_active IP Right Cessation
- 2005-06-15 HK HK12107145.5A patent/HK1166463A1/zh not_active IP Right Cessation
-
2006
- 2006-08-08 RU RU2006128796/15A patent/RU2342935C2/ru active
-
2007
- 2007-04-23 IL IL182742A patent/IL182742A0/en unknown
- 2007-08-17 FI FI20070322U patent/FI7846U1/fi not_active IP Right Cessation
- 2007-09-18 DK DK200700243U patent/DK200700243U3/da not_active IP Right Cessation
-
2009
- 2009-03-13 JP JP2009061144A patent/JP5107954B2/ja not_active Expired - Lifetime
- 2009-03-23 CY CY20091100346T patent/CY1108914T1/el unknown
- 2009-08-27 IL IL200621A patent/IL200621A/en active IP Right Grant
-
2010
- 2010-04-06 JP JP2010088165A patent/JP5932209B2/ja not_active Expired - Lifetime
-
2011
- 2011-09-30 US US13/251,172 patent/US20120108621A1/en not_active Abandoned
-
2012
- 2012-01-11 US US13/348,617 patent/US8846090B2/en not_active Expired - Lifetime
-
2013
- 2013-04-15 AR ARP130101201A patent/AR090677A2/es not_active Application Discontinuation
- 2013-10-18 US US14/058,068 patent/US20140045877A1/en not_active Abandoned
- 2013-10-18 US US14/058,108 patent/US8846091B2/en not_active Expired - Lifetime
-
2014
- 2014-03-04 JP JP2014041261A patent/JP2014129397A/ja active Pending
- 2014-06-16 US US14/305,785 patent/US9555000B2/en not_active Expired - Lifetime
- 2014-09-17 US US14/489,452 patent/US9655855B2/en not_active Expired - Lifetime
-
2015
- 2015-08-25 CY CY20151100735T patent/CY1116640T1/el unknown
-
2017
- 2017-01-05 US US15/399,487 patent/US9907793B2/en not_active Expired - Lifetime
- 2017-02-07 CY CY20171100165T patent/CY1118921T1/el unknown
- 2017-04-28 US US15/582,119 patent/US20170231978A1/en not_active Abandoned
- 2017-06-22 CY CY20171100665T patent/CY1119120T1/el unknown
- 2017-06-28 CY CY20171100683T patent/CY1119168T1/el unknown
-
2018
- 2018-01-26 US US15/881,459 patent/US10420762B2/en not_active Expired - Lifetime
- 2018-05-03 HK HK18105703.7A patent/HK1246176A1/zh unknown
- 2018-06-25 PH PH12018000176A patent/PH12018000176A1/en unknown
- 2018-09-11 HK HK18111654.4A patent/HK1254279A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE20308436U1 (de) | Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst | |
DE10038110B4 (de) | Pharmazeutische Zusammensetzungen | |
DE69434479T2 (de) | Tramadolhaltiges Arzneimittel mit gesteuerter Wirkstoffabgabe | |
ATE128028T1 (de) | Pharmazeutische zubereitung in form einer brause- und/oder zerfallstablette oder eines instantgranulats, sowie verfahren zu ihrer herstellung. | |
DD201643A5 (de) | Verfahren zur herstellung einer acetylsalicylsaeurehaltigen kapsel | |
EP1128831B1 (de) | Pharmazeutische zubereitung von moxifloxacin | |
UA29513C2 (uk) | Фармацевтична композиція, що включає (е)-3,5-дигідрокси-7-[4'-4''-фторфеніл-2'-циклопропілхінолін-3'-іл]-6- гептенову кислоту | |
SA01210740A (ar) | تركيب على شكل جرعات تؤخذ عن طريق الفم ممتدة الانطلاق. | |
EP0261181A1 (de) | Nifedipinkombinationspräparat. | |
DE60224194T3 (de) | Arzneizusammensetzungen enthaltend terbinafin und deren verwendung | |
DE102004011512A1 (de) | Pharmazeutische Zubereitung enthaltend Pimobendan | |
GB1296505A (de) | ||
DE102006044694A1 (de) | Perorale feste Schmerzmittelzubereitung | |
DE60225686T2 (de) | Paracetamol enthaltende tablette | |
IL99237A (en) | Preparation of a preparation in the form of a tablet or pill containing a compound sensitive to moisture, heat and light with a monoclinic crystal structure | |
EP0320550A1 (de) | NSAID-Zusammensetzungen mit Gehalt an H1-Blockern, H2-Blockern, beta-adrenergischen Agonisten oder Mischungen hiervon und an einem Alkalinisierungsmittel | |
KR101364561B1 (ko) | 압축성형제제 | |
CN104271125A (zh) | 用于治疗唾液酸缺乏的方法和制剂 | |
DE60303041T2 (de) | Fosinopril-formulierung | |
EP1575639A2 (de) | Arzneimittelabgabesystem zur verzögerten abgabe von glipizid | |
Feinstein et al. | Comparative study of selected disintegrating agents | |
CA2157921C (en) | Pharmaceutical compositions comprising paracetamol and l-cysteine or a precursor thereof | |
UA75566C2 (en) | Cyclophosphamide tablets, tablet cores, process for their manufacture | |
US5726201A (en) | Gemfibrozil containing pharmaceutical compositions | |
DE10215067A1 (de) | Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R207 | Utility model specification |
Effective date: 20031023 |
|
R081 | Change of applicant/patentee |
Owner name: EURO-CELTIQUE S.A., LU Free format text: FORMER OWNER: EUROCELTIQUE S.A., LUXEMBURG/LUXEMBOURG, LU Effective date: 20031105 |
|
R150 | Utility model maintained after payment of first maintenance fee after three years |
Effective date: 20060522 |
|
R151 | Utility model maintained after payment of second maintenance fee after six years |
Effective date: 20090515 |
|
R152 | Utility model maintained after payment of third maintenance fee after eight years |
Effective date: 20110517 |
|
R071 | Expiry of right | ||
R071 | Expiry of right |